COMP <GO>
SKYE vs SCNX // NET PROFIT MARGIN
Skye Bioscience Inc. (NASDAQ) VS. Scienture Holdings Inc. (NASDAQ) • 15-METRIC TALLY: SKYE 1
— SCNX 2
■ METRIC PARITY
LAST: $1.31 (-13.82%) • MKT CAP: $5.8M
net-margins
—
LAST: $3.49 (+2.65%) • MKT CAP: $5.7M
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SKYE VS. SCNX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SKYE | SCNX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 76.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 4/9 | -2.00 | SCNX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.0 | 32.0 | -1.02 | SCNX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.8M | $5.7M | $67.7K | SKYE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SKYE REV | SCNX REV | SKYE GROSS % | SCNX GROSS % | SKYE FCF | SCNX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $431.6K | — | 76.8% | -$43.1M | -$13.4M |
| FY 2024 | $0 | $136.6K | — | 4.4% | -$26.8M | -$14.3M |
| FY 2023 | $0 | $1.4M | — | — | -$14.0M | -$2.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SKYE // BETA —
SCNX // BETA —